Up a level |
Herrlinger, Ulrich, Tzaridis, Theophilos, Mack, Frederic, Steinbach, Joachim, Schlegel, Uwe, Sabel, Michael, Hau, Peter, Kortman, Rolf-Dieter, Krex, Dietmar, Grauer, Oliver, Goldbrunner, Roland, Schnell, Oliver, Baehr, Oliver, Uhl, Martin, Tabatabai, Ghazaleh, Ringel, Florian, Schmidt-Graf, Friederike, Brehmer, Stefanie, Weyerbrock, Astrid, Bullinger, Lars, Vajkoczy, Peter, Vatter, Hartmut, Schaefer, Niklas, Kebir, Sied, Weller, Johannes, Stummer, Walter, Simon, Matthias, Keil, Vera ORCID: 0000-0001-8699-3506, Nelles, Michael, Fimmers, Rolf, Pietsch, Torsten, Hattingen, Elke, Coch, Christoph and Glas, Martin (2017). PHASE III TRIAL OF CCNU/TEMOZOLOMIDE (TMZ) COMBINATION THERAPY VS. STANDARD TMZ THERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED GLIOBLASTOMA PATIENTS: THE CeTeg/NOA-09 trial. Neuro-Oncology, 19. S. 13 - 15. CARY: OXFORD UNIV PRESS INC. ISSN 1523-5866
Herrlinger, Ulrich, Tzaridis, Theophilos ORCID: 0000-0001-9651-1144, Mack, Frederic, Steinbach, Joachim Peter, Schlegel, Uwe, Sabel, Michael, Hau, Peter ORCID: 0000-0003-3894-5053, Kortmann, Rolf-Dieter, Krex, Dietmar, Grauer, Oliver, Goldbrunner, Roland, Schnell, Oliver, Baehr, Oliver, Uhl, Martin, Seidel, Clemens, Tabatabai, Ghazaleh ORCID: 0000-0002-3542-8782, Kowalski, Thomas, Ringel, Florian, Schmidt-Graf, Friederike, Suchorska, Bogdana, Brehmer, Stefanie, Weyerbrock, Astrid ORCID: 0000-0001-9060-4462, Renovanz, Miriam, Bullinger, Lars, Galldiks, Norbert ORCID: 0000-0002-2485-1796, Vajkoczy, Peter, Misch, Martin, Vatter, Hartmut, Stuplich, Moritz, Schaefer, Niklas, Kebir, Sied, Weller, Johannes ORCID: 0000-0001-5818-5392, Schaub, Christina, Stummer, Walter, Tonn, Joerg-Christian, Simon, Matthias, Keil, Vera C., Nelles, Michael, Urbach, Horst, Coenen, Martin, Wick, Wolfgang ORCID: 0000-0002-6171-634X, Weller, Michael, Fimmers, Rolf, Schmid, Matthias ORCID: 0000-0002-0788-0317, Hattingen, Elke ORCID: 0000-0002-8392-9004, Pietsch, Torsten, Coch, Christoph and Glas, Martin (2019). Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Lancet, 393 (10172). S. 678 - 689. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-547X
Kebir, Sied, Schaub, Christina, Junold, Nina, Hattingen, Elke ORCID: 0000-0002-8392-9004, Schaefer, Niklas, Steinbach, Joachim P., Weyerbrock, Astrid ORCID: 0000-0001-9060-4462, Hau, Peter, Goldbrunner, Roland, Galldiks, Norbert ORCID: 0000-0002-2485-1796, Weller, Johannes ORCID: 0000-0001-5818-5392, Mack, Frederic, Tzaridis, Theophilos ORCID: 0000-0001-9651-1144, Baehr, Oliver, Seidel, Clemens, Schlegel, Uwe, Schmidt-Graf, Friederike, Rohde, Veit, Borchers, Christian, Tabatabai, Ghazaleh ORCID: 0000-0002-3542-8782, Haenel, Mathias, Sabel, Michael, Gerlach, Ruediger, Krex, Dietmar, Belka, Claus, Vatter, Hartmut, Proescholdt, Martin, Glas, Martin and Herrlinger, Ulrich (2019). Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial. J. Neuro-Oncol., 144 (3). S. 501 - 510. NEW YORK: SPRINGER. ISSN 1573-7373
Tzaridis, Theophilos, Reiners, Katrin S., Weller, Johannes, Bachurski, Daniel ORCID: 0000-0001-9168-9680, Schaefer, Niklas, Schaub, Christina, Hallek, Michael, Scheffler, Bjoern, Glas, Martin, Herrlinger, Ulrich, Wild, Stefan, Coch, Christoph and Hartmann, Gunther (2020). Analysis of Serum miRNA in Glioblastoma Patients: CD44-Based Enrichment of Extracellular Vesicles Enhances Specificity for the Prognostic Signature. Int. J. Mol. Sci., 21 (19). BASEL: MDPI. ISSN 1422-0067
Tzaridis, Theophilos ORCID: 0000-0001-9651-1144, Schaefer, Niklas, Weller, Johannes, Steinbach, Joachim-Peter, Schlegel, Uwe, Seidel, Sabine, Sabel, Michael, Hau, Peter, Seidel, Clemens, Krex, Dietmar, Goldbrunner, Roland, Tonn, Joerg-Christian, Grauer, Oliver, Kebir, Sied, Schneider, Matthias, Schaub, Christina, Vatter, Hartmut, Coch, Christoph, Glas, Martin, Fimmers, Rolf, Pietsch, Torsten, Reifenberger, Guido, Herrlinger, Ulrich and Felsberg, Joerg . MGMT promoter methylation analysis for allocating combined CCNU/TMZ chemotherapy: Lessons learned from the CeTeG/NOA-09 trial. Int. J. Cancer. HOBOKEN: WILEY. ISSN 1097-0215
Tzaridis, Theophilos, Weller, Johannes, Bachurski, Daniel ORCID: 0000-0001-9168-9680, Schaefer, Niklas, Schaub, Christina, Hallek, Michael, Scheffler, Bjoern, Glas, Martin, Hartmann, Gunther, Herrlinger, Ulrich, Wild, Stefan, Coch, Christoph and Reiners, Katrin (2020). ANALYSIS OF SERUM MIRNA IN GLIOBLASTOMA PATIENTS: TARGETED ENRICHMENT OF EXTRACELLULAR VESICLES ENHANCES SPECIFICITY FOR PROGNOSTIC SIGNATURE. Neuro-Oncology, 22. S. 10 - 11. CARY: OXFORD UNIV PRESS INC. ISSN 1523-5866
Tzaridis, Theophilos ORCID: 0000-0001-9651-1144, Weller, Johannes, Bachurski, Daniel ORCID: 0000-0001-9168-9680, Shakeri, Farhad ORCID: 0000-0003-1161-1942, Schaub, Christina, Hau, Peter, Buness, Andreas, Schlegel, Uwe, Steinbach, Joachim-Peter, Seidel, Clemens, Goldbrunner, Roland, Schaefer, Niklas, Wechsler-Reya, Robert J., Hallek, Michael ORCID: 0000-0002-7425-4455, Scheffler, Bjoern, Glas, Martin, Haeberle, Lothar, Herrlinger, Ulrich, Coch, Christoph, Reiners, Katrin S. and Hartmann, Gunther (2023). A novel serum extracellular vesicle protein signature to monitor glioblastoma tumor progression. Int. J. Cancer, 152 (2). S. 308 - 320. HOBOKEN: WILEY. ISSN 1097-0215
Weller, Johannes ORCID: 0000-0001-5818-5392, Schaefer, Niklas, Schaub, Christina, Potthoff, Anna-Laura, Steinbach, Joachim P., Schlegel, Uwe, Sabel, Michael ORCID: 0009-0000-1485-7820, Hau, Peter, Seidel, Clemens, Krex, Dietmar, Goldbrunner, Roland, Pietsch, Torsten, Tzaridis, Theophilos, Zeyen, Thomas, Borger, Valeri, Guresir, Erdem, Vatter, Hartmut, Herrlinger, Ulrich and Schneider, Matthias (2022). Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS. J. Neuro-Oncol., 159 (1). S. 95 - 102. NEW YORK: SPRINGER. ISSN 1573-7373
Weller, Johannes ORCID: 0000-0001-5818-5392, Tzaridis, Theophilos ORCID: 0000-0001-9651-1144, Mack, Frederic, Steinbach, Joachim Peter, Schlegel, Uwe, Hau, Peter, Krex, Dietmar, Grauer, Oliver, Goldbrunner, Roland, Baehr, Oliver, Uhl, Martin, Seidel, Clemens, Tabatabai, Ghazaleh ORCID: 0000-0002-3542-8782, Brehmer, Stefanie, Bullinger, Lars, Galldiks, Norbert ORCID: 0000-0002-2485-1796, Schaub, Christina, Kebir, Sied, Stummer, Walter, Simon, Matthias, Fimmers, Rolf, Coch, Christoph, Glas, Martin, Herrlinger, Ulrich and Schaefer, Niklas (2019). Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol., 20 (10). S. 1444 - 1454. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-5488
Weller, Johannes, Tzaridis, Theophilos, Steinbach, Joachim, Schlegel, Uwe, Hau, Peter, Krex, Dietmar, Grauer, Oliver, Goldbrunner, Roland, Baehr, Oliver, Uhl, Martin, Seidel, Clemens, Tabatabai, Ghazaleh, Bullinger, Lars, Galldiks, Norbert ORCID: 0000-0002-2485-1796, Schaub, Christina, Stummer, Walter, Simon, Matthias, Fimmers, Rolf, Matthias, Schmid, Coch, Christoph, Glas, Martin, Herrlinger, Ulrich and Schaefer, Niklas (2018). QUALITY OF LIFE IN THE PHASE III CeTeG/NOA-09 TRIAL RANDOMIZING CCNU/TEMOZOLOMIDE (TMZ) COMBINATION THERAPY VS. STANDARD TMZ THERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED GLIOBLASTOMA. Neuro-Oncology, 20. S. 218 - 220. CARY: OXFORD UNIV PRESS INC. ISSN 1523-5866
Werner, Jan-Michael, Ceccon, Garry, Weller, Johannes, Schaub, Christina, Tscherpel, Caroline, Lohmann, Philipp, Bauer, Elena, Schaefer, Niklas, Stoffels, Gabriele, Kabbasch, Christoph, Baues, Christian, Marnitz, Simone, Fink, Gereon R., Langen, Karl-Josef, Herrlinger, Ulrich and Galldiks, Norbert (2020). DIAGNOSIS OF PSEUDOPROGRESSION FOLLOWING RADIOTHERAPY PLUS LOMUSTINE-TEMOZOLOMIDE CHEMOTHERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS USING FET PET. Neuro-Oncology, 22. S. 152 - 155. CARY: OXFORD UNIV PRESS INC. ISSN 1523-5866
Werner, Jan-Michael ORCID: 0000-0001-7147-4594, Weller, Johannes, Ceccon, Garry, Schaub, Christina, Tscherpel, Caroline, Lohmann, Philipp ORCID: 0000-0002-5360-046X, Bauer, Elena K., Schaefer, Niklas, Stoffels, Gabriele, Baues, Christian, Celik, Eren, Marnitz, Simone, Kabbasch, Christoph, Gielen, Gerrit H., Fink, Gereon R. ORCID: 0000-0002-8230-1856, Langen, Karl-Josef, Herrlinger, Ulrich and Galldiks, Norbert (2021). Diagnosis of Pseudoprogression Following Lomustine-Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET. Clin. Cancer Res., 27 (13). S. 3704 - 3714. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1557-3265
Zeyen, Thomas, Potthoff, Anna-Laura, Nemeth, Robert, Heiland, Dieter H., Burger, Michael C., Steinbach, Joachim P., Hau, Peter, Tabatabai, Ghazaleh, Glas, Martin, Schlegel, Uwe, Grauer, Oliver, Krex, Dietmar, Schnell, Oliver, Goldbrunner, Roland, Sabel, Michael ORCID: 0009-0000-1485-7820, Thon, Niklas, Delev, Daniel, Clusmann, Hans, Seidel, Clemens, Gueresir, Erdem, Schmid, Matthias ORCID: 0000-0002-0788-0317, Schuss, Patrick ORCID: 0000-0002-5806-2576, Giordano, Frank A., Radbruch, Alexander, Becker, Albert, Weller, Johannes, Schaub, Christina, Vatter, Hartmut, Schilling, Judith, Winkler, Frank ORCID: 0000-0003-4892-6104, Herrlinger, Ulrich and Schneider, Matthias (2022). Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy-the MecMeth/NOA-24 trial. Trials, 23 (1). LONDON: BMC. ISSN 1745-6215